DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Parkinson’s Disease – Access & Reimbursement – Access & Reimbursement – Parkinson’s Disease (US)
Since 2015, eight new brands have launched into the highly generic U.S. Parkinson’s disease (PD) therapy market, and six more are expected to launch soon. Chronic polypharmacy and progressive…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Epidemiology – Americas
Clarivate Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprises epidemiological estimates of key patient populations in 45 countries worldwide…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Epidemiology – Emerging Markets
Clarivate Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprises epidemiological estimates of key patient populations in 45 countries worldwide…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprises epidemiological estimates of key patient populations in 45 countries worldwide…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of NHL comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and diagnosed prevalence…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Epidemiology – Extrapolated Worldwide Coverage
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key NHL patient populations covering 171 countries and more than 99% of…
